In-vivo proof of concept in malignant melanoma

10-Feb-2012 - Sweden

LU Bio portfolio company Cantargia has achieved in-vivo proof of concept targeting IL1RAP expressing human tumor. The concept of targeting IL1RAP has with these findings been further validated. The results show highly significant inhibition of tumor growth in a transplanted in-vivo model of human malignant melanoma, this as a result of the treatment with a Cantariga-developed anti-IL1RAP monoclonal antibody.

LU Bio has in total invested SEK 6,8 million in Cantargia and holds a position of 53%, others being the founders.

The company has previously presented significant anti malignant effects in an ex-vivo model of human leukemia. The project is based on the original discovery of IL1RAP as a unique receptor on leukemic stem cells in patients with chronic myeloid leukemia. The IL1RAP receptor has also been shown to be up-regulated on stem cells of AML and ALL.

"These results validate the concept in-vivo as well as represent an additional therapeutic target for an antibody based therapy against IL1RAP" says Agneta Svedberg, CEO of Cantargia. 

Other news from the department research and development

Most read news

More news from our other portals

So close that even
molecules turn red...

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous